Read SURMOUNT‑1 for follow-up duration and the control group
This 2022 Phase 3 trial compared tirzepatide with placebo in adults with overweight or obesity without diabetes and reported weight outcomes at 72 weeks.
Research
Track clinical research, regulatory updates, and primary sources on GLP‑1 and metabolism.
Research
Body Education
Agent Projects
November 2026
MonTueWedThuFriSatSun
Research
6 casesWhat was the primary endpoint in SELECT?
Published in 2023, this randomized trial enrolled adults with overweight or obesity and established cardiovascular disease without diabetes. Its primary endpoint covered major cardiovascular events.
How did Fractyl document its development decision?
In its October 22, 2026 disclosure, Fractyl said it would stop internal development of its Rejuva gene therapy program and explore other options.
Read a GLP‑1 drug labeling update
On November 9, 2026, the U.S. FDA announced required GLP‑1 receptor agonist labeling changes concerning the potential risk of NAION, a rare optic nerve disorder.
What did the early CTX310 study measure?
On November 9, 2026, CRISPR Therapeutics announced Phase 1b results for CTX310, reporting changes in blood lipid measures among participants with severe hypertriglyceridemia.
Read STEP 1 as a randomized controlled trial
This 2021 double-blind study compared weight outcomes with semaglutide and placebo in adults with overweight or obesity without diabetes over 68 weeks.